Business Description
Cyclo Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US12642Q1013
Description
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 8.95 | |||||
| Equity-to-Asset | 0.36 | |||||
| Debt-to-Equity | 0.22 | |||||
| Debt-to-EBITDA | -0.05 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -10.36 | |||||
| Beneish M-Score | -1.53 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -51.1 | |||||
| 3-Year EBITDA Growth Rate | 39.7 | |||||
| 3-Year EPS without NRI Growth Rate | 39.7 | |||||
| 3-Year FCF Growth Rate | 43.1 | |||||
| 3-Year Book Growth Rate | -57.6 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 78.96 | |||||
| 9-Day RSI | 68.34 | |||||
| 14-Day RSI | 60.61 | |||||
| 6-1 Month Momentum % | 34.65 | |||||
| 12-1 Month Momentum % | 4.62 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.45 | |||||
| Quick Ratio | 1.42 | |||||
| Cash Ratio | 1.09 | |||||
| Days Inventory | 1054.54 | |||||
| Days Sales Outstanding | 47.53 | |||||
| Days Payable | 16598.7 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -81.6 | |||||
| Shareholder Yield % | -23.12 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 92.28 | |||||
| Operating Margin % | -1865.12 | |||||
| Net Margin % | -1865.67 | |||||
| FCF Margin % | -1505.58 | |||||
| ROE % | -3987.28 | |||||
| ROA % | -315.35 | |||||
| ROIC % | -2077.29 | |||||
| ROC (Joel Greenblatt) % | -7887.49 | |||||
| ROCE % | -3807.44 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 22.54 | |||||
| PB Ratio | 9.04 | |||||
| Price-to-Tangible-Book | 9.04 | |||||
| EV-to-EBIT | -1.75 | |||||
| EV-to-EBITDA | -1.75 | |||||
| EV-to-Revenue | 32.69 | |||||
| EV-to-Forward-Revenue | 18.05 | |||||
| EV-to-FCF | -2.17 | |||||
| Price-to-Median-PS-Value | 1.15 | |||||
| Price-to-Net-Current-Asset-Value | 11.61 | |||||
| Price-to-Net-Cash | 50.33 | |||||
| Earnings Yield (Greenblatt) % | -57.14 | |||||
| FCF Yield % | -37.33 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CYTH
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cyclo Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1.075 | ||
| EPS (TTM) ($) | -1.31 | ||
| Beta | 1 | ||
| Volatility % | 78.11 | ||
| 14-Day RSI | 60.61 | ||
| 14-Day ATR ($) | 0.1131 | ||
| 20-Day SMA ($) | 1.328 | ||
| 12-1 Month Momentum % | 4.62 | ||
| 52-Week Range ($) | 0.8924 - 2.57 | ||
| Shares Outstanding (Mil) | 28.72 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cyclo Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cyclo Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cyclo Therapeutics Inc Frequently Asked Questions
What is Cyclo Therapeutics Inc(CYTH)'s stock price today?
The current price of CYTH is $1.51. The 52 week high of CYTH is $2.57 and 52 week low is $0.89.
When is next earnings date of Cyclo Therapeutics Inc(CYTH)?
The next earnings date of Cyclo Therapeutics Inc(CYTH) is 2024-05-10 Est..
Does Cyclo Therapeutics Inc(CYTH) pay dividends? If so, how much?
Cyclo Therapeutics Inc(CYTH) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers